Skip to main content
. Author manuscript; available in PMC: 2010 Apr 22.
Published in final edited form as: Mol Pharmacol. 2008 Apr 29;74(2):360–370. doi: 10.1124/mol.108.046813

Figure 3. Disruption of the PSD-95/NMDAR interaction facilitates calpain regulation of NMDAR-EPSC.

Figure 3

A, Effect of TAT-NR2CT peptide (25 µM, 30 min treatment) on the interaction of NMDA receptors with PSD-95. A scrambled peptide was used as a control. After treatment, cell lysates from cortical slices were immunoprecipitated with anti-PSD-95 and Western blotted with anti-NR2A, anti-NR2B or PSD-95. B, Bar graphs showing levels of NR2A and NR2B bound to PSD-95 in the absence or presence of TAT-NR2CT peptide or a scrambled peptide. *: p < 0.001, ANOVA. C, Plot of normalized peak NMDAR-EPSC showing the effect of prolonged NMDA treatment (100 µM, 5 min) in neurons dialyzed with or without TAT-NR2CT peptide (10 µM) in the absence or presence of calpain inhibitor ALLN (25 µM). Inset: Representative traces (average of 3 trials) taken from the recordings used to construct C (at time points denoted by numbers). Scale bars: 100 pA, 100 ms. D, Cumulative data (mean ± SEM) summarizing the percentage reduction of NMDAR-EPSC amplitude by prolonged NMDA treatment under different conditions. *: p < 0.001, ANOVA.